Clinical Trial Update: Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating BXCL501 for efficacy and safety in agitation associated with pediatric schizophrenia and related disorders, including schizo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Bipolar Ii Disorder
• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Drugs mentioned

• BXCL501 (dexmedetomidine)

Snippet

Sponsor: BioXcel Therapeutics Inc | Conditions: Schizophrenia, Schizo-Affective Disorder | Phase 1 | Status: RECRUITING